Definium Therapeutics Gains FDA Breakthrough Therapy Designation for DT120 in MDD
NEW YORK — September 8, 2026 Definium Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
GAD
Advertisement
Helus Pharma Completes Phase 3 HLP003 Enrollment in MDD
NEW YORK and TORONTO, Aug. 14, 2026 Helus Pharma is advancing its late-stage clinical development strategy for novel serotonergic...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
AtaiBeckley Completes Patient Dosing in Phase 2b VLS-01 TRD Trial
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
PureTech and Seaport Report Positive GlyphAgo Phase 1 Data
BOSTON, June 8, 2026 PureTech Health and its Founded Entity Seaport Therapeutics announced positive results from the multiple-ascending dose...
Advertisement
